Hepatitic variant of graft-versus-host disease after donor lymphocyte infusion

被引:69
作者
Akpek, G [1 ]
Boitnott, JK [1 ]
Lee, LA [1 ]
Hallick, JP [1 ]
Torbenson, M [1 ]
Jacobsohn, DA [1 ]
Arai, S [1 ]
Anders, V [1 ]
Vogelsang, GB [1 ]
机构
[1] Johns Hopkins Univ, Sch Med, Sidney Kimmel Comprehens Canc Ctr, Dept Oncol Pathol & Med, Baltimore, MD 21231 USA
关键词
D O I
10.1182/blood-2002-03-0857
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Graft-versus-host disease (GVHD) of the liver is characterized by bile duct damage and portal lymphocytic infiltrate. We report acute hepatitislike presentation of GVHD after donor lymphocyte infusion (DLI). Between April 1998 and September 2001, 73 patients received 94 DLI treatments. Liver GVHD developed after DLI in 22 (30%) patients whose median age was 43 years (range, 21 to 61 years). Onset of liver dysfunction was at 35 days (range, 11 to 406 days) after DLI. Fifteen patients underwent liver biopsy, and the diagnosis of liver GVHD was confirmed in 13 (87%) patients. After viral hepatitis and recent drug exposure were excluded, 11 (50%) patients were given a diagnosis of a hepatitic variant of GVHD based on histologic evidence of lobular hepatitis (n = 5), elevation of maximum serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level more than 10 times the upper normal limit (n = 9), or both. There was a significant difference in maximum ALT (P = .002) and AST (P = .01) level between the hepatitic-variant and classical GVHD groups. GVHD progressed in 14 (64%) patients, and 10 patients died after a median follow-up of 221 days (range, 31-1284 days). These observations suggest that GVHD that occurs after DLI may have distinct clinical features. Hepatitic-variant GVHD should be considered in the differential diagnosis in DLI recipients with unexplained hepatitis. (C) 2002 by The American Society of Hematology.
引用
收藏
页码:3903 / 3907
页数:5
相关论文
共 24 条
[1]   T-cell-depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect [J].
Alyea, E ;
Weller, E ;
Schlossman, R ;
Canning, C ;
Webb, I ;
Doss, D ;
Mauch, P ;
Marcus, K ;
Fisher, D ;
Freeman, A ;
Parikh, B ;
Gribben, J ;
Soiffer, R ;
Ritz, J ;
Anderson, K .
BLOOD, 2001, 98 (04) :934-939
[2]  
BESCHORNER WE, 1980, AM J PATHOL, V99, P369
[3]   Prophylactic donor lymphocyte infusions after moderately ablative chemotherapy and stem cell transplantation for hematological malignancies: high remission rate among poor prognosis patients at the expense of graft-versus-host disease [J].
de Lima, M ;
Bonamino, M ;
Vasconcelos, Z ;
Colares, M ;
Diamond, H ;
Zalcberg, I ;
Tavares, R ;
Lerner, D ;
Byington, R ;
Bouzas, L ;
da Matta, J ;
Andrade, C ;
Carvalho, L ;
Pires, V ;
Barone, B ;
Maciel, C ;
Tabak, D .
BONE MARROW TRANSPLANTATION, 2001, 27 (01) :73-78
[4]   Hepatic graft-versus-host disease presenting as an acute hepatitis after allogeneic peripheral blood stem cell transplantation [J].
Fujii, N ;
Takenaka, K ;
Shinagawa, K ;
Ikeda, K ;
Maeda, Y ;
Sunami, K ;
Hiramatsu, Y ;
Matsuo, K ;
Ishimaru, F ;
Niiya, K ;
Yoshino, T ;
Hirabayashi, N ;
Harada, M .
BONE MARROW TRANSPLANTATION, 2001, 27 (09) :1007-1010
[5]   Differential effects of anti-Fas ligand and anti-tumor necrosis factor α antibodies on acute graft-versus-host disease pathologies [J].
Hattori, K ;
Hirano, T ;
Miyajima, H ;
Yamakawa, N ;
Tateno, M ;
Oshimi, K ;
Kayagaki, N ;
Yagita, H ;
Okumura, K .
BLOOD, 1998, 91 (11) :4051-4055
[6]   The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation [J].
Hill, GR ;
Ferrara, JLM .
BLOOD, 2000, 95 (09) :2754-2759
[7]  
Hill GR, 1997, CYTOKINES CELL MOL T, V3, P257
[8]   Therapeutic effect of novel anti-human Fas antibody HFE7A on graft-versus-host disease model [J].
Kuwahara, H ;
Tani, Y ;
Ogawa, Y ;
Takaichi, Y ;
Shiraishi, A ;
Ohtsuki, M .
CLINICAL IMMUNOLOGY, 2001, 99 (03) :340-346
[9]   Prospective trial of chemotherapy and donor leukocyte infusions for relapse of advanced myeloid malignancies after allogeneic stem-cell transplantation [J].
Levine, JE ;
Braun, T ;
Penza, SL ;
Beatty, P ;
Cornetta, K ;
Martino, R ;
Drobyski, WR ;
Barrett, AJ ;
Porter, DL ;
Giralt, S ;
Leis, J ;
Holmes, HE ;
Johnson, M ;
Horowitz, M ;
Collins, RH .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (02) :405-412
[10]   Contributions of donor CD4 and CD8 cells to liver injury during murine graft-versus-host disease [J].
Li, JA ;
Helm, K ;
Howell, CD .
TRANSPLANTATION, 1996, 62 (11) :1621-1628